Friday, 24 Jan 2020

You are here

Alpha-1-Anti-Trypsin-Fc Fusion Protein Ameliorates Gouty Arthritis

Gout is the most common inflammatory arthritis affecting adults and, probably, one of the most underestimated.

Besides damaging joints and causing significant pain and disability, there are pathogenic mechanisms by which uric acid participates in the development of numerous comorbidities - including cardiovascular disease. 
 
Prevention and early treatment of acute gout not only decreases the disability and economic burden associated with it, but may also lessen the impact of CV and other comorbidities. Hence, finding new ways to quickly and effectively resolve acute flares of gout could be priceless.
 
Joosten et al has generated a new protein, recombinant human alpha-1-anti-trypsin (AAT)-IgG1 Fc fusion protein (AAT-Fc), to evaluate its antiinflammatory potential in and IL-1 induced animal model of gouty arthritis. A single low dose of AAT-Fc was shown to be highly effective in reducing joint inflammation in an animal model of acute gouty arthritis. Considering the long-term safety of plasma-derived AAT use in humans, subcutaneous AAT-Fc may emerge as a promising therapy for gout attacks.
Disclosures: 
The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

Diabetics using SGLT2 Inhibitors have a lower Gout Risk

Researchers from the Brigham and Women's Hospital have reported that adults with type 2 diabetes who were treated with SGLT2 inhibitors had a lower risk of gout compared to GLP1 agonist, suggesting that sodium–glucose cotransporter-2 inhibitors may reduce the risk for gout with type 2 diabetes mellitus (T2DM).

A Role for SGLT2 Inhibition in Gout?

The antidiabetic medication canagliflozin (Invokana) lowered serum urate and reduced the risk of gout flare in a post-hoc analysis of data from two large clinical trials.

Predicting Inpatient Gout Flares

Analysis of New Zealand hospitalized patients revals nine predictors of inpatient flare for people with comorbid gout.

This retrospective cohort study of hospitalised patients with comorbid gout included 625 hospitalised patients, 87 experienced inpatient gout flare.

There were 9 predictors of an inpatient gout flare:

Pegradicase+ImmTOR SEL-212 Shows Promising Results In Active Gout

Therapies targeting sUA accumulation or improving its excretion are widely used for treatment of symptoms and prevention of progression of gout for decades. Despite our best effort, there is still a significant amount of patients who remain symptomatic and/or experiences progressive joint damage and disability. Regardless of the cause, either its lack of compliance or poor tolerability, more effective treatments are needed.

PANLAR Ultrasound Study Group: Recommendations On Imaging Modalities In Gout

Gout is a systemic inflammatory disease with high potential for joint damage due to erosive changes and MSU deposits resulting in disability and chronic pain. Prompt diagnosis and effective treatment are key to better long term outcomes and decreased disability.